Article

FDA approves two devices for treatment of OAB

The FDA has granted approval to two devices indicated for the treatment of overactive bladder.

The FDA has granted approval to two devices indicated for the treatment of overactive bladder.

Uroplasty, Inc.’s Urgent PC Neuromodulation System is a non-surgical nerve stimulation device designed for office-based treatment of overactive bladder symptoms. The minimally invasive device uses targeted neurostimulation to disrupt the signals that trigger urinary urgency and frequency.

Medtronic Inc.’s InterStim II system has gained FDA approval for the treatment of intractable cases of overactive bladder and urinary retention. The InterStim II adds a new implantable neurostimulator, improved patient programmer, and upgraded software for the clinician programmer. It is a smaller, lighter version of the original InterStim device, which received FDA approval in 1997.

Related Videos
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Daniel Carson, MD, MS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.